Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Qualitative Hybrid III Implementation Study to Identify and Evaluate Strategies for Successful Implementation of the Cabotegravir + Rilpivirine Long-acting Injectable Regimen in the US

NCT04001803 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT04001803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04001803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Qualitative Hybrid III Implementation Study to Identify and Evaluate Strategies for Successful Implementation of the Cabotegravir + Rilpivirine Long-acting Injectable Regimen in the US
Lead sponsor
ViiV Healthcare
Phase
Phase 3
Overall status
Completed
Start date
July 8, 2019
Completion date
March 18, 2022
Enrollment
115 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections